Eric counsels life sciences clients navigating the complex world of patent law across the chemical, biotech, and pharmaceutical sectors. From positioning intellectual property portfolios for early-stage investments to leading IP diligence on buy- and sell-side asset acquisitions, Eric blends hands-on experience with advanced technologies and strategic insight.

As a trusted business adviser, Eric conducts IP diligence for IPOs, licensing deals, mergers and acquisitions, and other financial transactions. Drawing on his experience managing patent strategy for both platform innovations and late-stage FDA-approved assets, Eric develops IP positions that sharpen his clients’ competitive edge and help ensure their innovations withstand generic challenges and reach full revenue potential. When not involved at an early stage, Eric is often sought for pre-litigation support to pressure-test key exclusivity patents, assess risk, and devise remedial solutions.

Eric’s technological experience spans the full spectrum of life sciences, including small molecule drugs, protein and polypeptide therapeutics, antibody therapeutics, oligonucleotides, lipid nanoparticle technology, antibody-drug conjugates (ADCs), molecular glues, proteolysis targeting chimeras (PROTACs), psychedelics, natural products and derivatives, prodrugs, pharmaceutical formulations, solid forms and polymorphs, dosing methodology, therapeutic combinations, organic synthesis, polymer chemistry and materials, analytical methodology, analytical devices, stents, implantable pain management devices, imaging technologies such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), near-infrared (NIR), photoacoustic, etc., fluorescent sensors, photodynamic therapy, bioanalytical chemistry, MRI analysis software, cosmetics, and consumer products.